Evidence map›Paper›PMID 24788895›Full record

ReviewMetabolic brain disease2015

Epigenetic impact of curcumin on stroke prevention.

Anuradha Kalani, Pradip K Kamat, Komal Kalani, Neetu Tyagi

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Metabolic brain disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. The Role of Supplementation with Natural Compounds in Post-Stroke Patients.International journal of molecular sciences · 2021
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Anuradha KalaniDepartment of Physiology and Biophysics, School of Medicine, Health Sciences Centre, A-1201, University of Louisville, 500 South Preston Street, Louisville, KY, 40202, USA.
Pradip K Kamat
Komal Kalani
Neetu Tyagi
University of Louisville · USCentral Institute of Medicinal and Aromatic Plants · INUniversity of Louisville Hospital · US

Funding

Mechanisms of Mitochondrial Dysfunction in Brain VasculatureR01HL107640 · NHLBI · UNIVERSITY OF LOUISVILLE · PI TYAGI, NEETU · 2012 to 2016
$1.8M
NHLBI NIH HHS HL107640-NTNHLBI NIH HHS R01 HL107640
6 · The paper itself

Abstract

The epigenetic impact of curcumin in stroke and neurodegenerative disorders is curiosity-arousing. It is derived from Curcuma longa (spice), possesses anti-oxidative, anti-inflammatory, anti-lipidemic, neuro-protective and recently shown to exhibit epigenetic modulatory properties. Epigenetic studies include DNA methylation, histone modifications and RNA-based mechanisms which regulate gene expression without altering nucleotide sequences. Curcumin has been shown to affect cancer by altering epigenetic changes but its role as an epigenetic agent in cerebral stroke has not been much explored. Although curcumin possesses remarkable medicinal properties, the bioavailability of curcumin has limited its success in epigenetic studies and clinical trials. The present review is therefore designed to look into epigenetic mechanisms that could be induced with curcumin during stroke, along with its molecular designing with different moieties that may increase its bioavailability. Curcumin has been shown to be encapsulated in exosomes, nano-vesicles (<200 nm), thereby showing its therapeutic effects in brain diseases. Curcumin delivered through nanoparticles has been shown to be neuroregenerative but the use of nanoparticles in brain has limitations. Hence, curcumin-encapsulated exosomes along with curcumin-primed exosomes (exosomes released by curcumin-treated cells) are much needed to be explored to broadly look into their use as a novel therapy for stroke.

Indexed as

AnimalsAnti-Inflammatory Agents, Non-SteroidalCurcuminEpigenesis, GeneticExosomesHumansNeuroprotective AgentsStrokeAnti-Inflammatory Agents, Non-SteroidalCurcuminNeuroprotective Agents

Identifiers

PMID24788895
PMCPMC4216637
OpenAlexW2031257097

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.